| Literature DB >> 32999052 |
Matthew M Kavanagh1,2, Ellie Graeden3, Mara Pillinger4, Renu Singh4, Stephanie Eaneff3, Victoria Bendaud5, Rico Gustav6, Taavi Erkkola5.
Abstract
Law and policy differences help explain why, as HIV-related science has advanced swiftly, some countries have realised remarkable progress on AIDS while others see expanding epidemics. We describe the structure and findings of a new dataset and research platform, the HIV Policy Lab, which fills an important knowledge gap by measuring the HIV-related policy environment across 33 indicators and 194 countries over time, with online access and visualisation. Cross-national indicators can be critical tools in international governance-building social power to monitor state behaviour with the potential to change policy and improve domestic accountability. This new and evolving effort collects data about policy through review of legal documents, official government reports and systematic review of secondary sources. Alignment between national policy environments and global norms is demonstrated through comparison with international public health guidance and agreements. We demonstrate substantial variation in the content of law and policies between countries, regions and policy areas. Given progress in basic and implementation science, it would be tempting to believe most countries have adopted policies aligned with global norms, with a few outliers. Data show this is not the case. Globally, alignment is higher on clinical and treatment policies than on prevention, testing and structural policies. Policy-makers, researchers, civil society, finance agencies and others can use these data to better understand the policy environment within and across countries and support reform. Longitudinal analysis enables evaluation of the impact of laws and policies on HIV outcomes and research about the political drivers of policy choice. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: AIDS; HIV; health policy; tuberculosis
Mesh:
Year: 2020 PMID: 32999052 PMCID: PMC7528353 DOI: 10.1136/bmjgh-2020-003695
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
HIV policy indicators
| Indicator number | Name | Coding question |
| CT1 | Treatment Initiation | Do national guidelines on when to initiate HIV treatment align with international recommendations? |
| CT2 | Same-day treatment start | Do national HIV treatment guidelines offer the possibility to start antiretrovial therapy (ART) the same day as HIV diagnosis? |
| CT3 | Treatment regimen | Does the first-line antiretrovial (ARV) regimen included in national HIV treatment guidelines align with international recommendations? |
| CT4 | Differentiated service delivery | Do national HIV guidelines incorporate differentiated service delivery for stable patients? |
| CT5 | Viral load testing | Do national guidelines on frequency of viral load monitoring align with international recommendations? |
| CT6 | Paediatric diagnosis and treatment | Do national guidelines for paediatric testing and treatment align with international recommendations? |
| CT7 | Migrant access to healthcare | Do national laws/policies allow all migrants access to HIV and primary healthcare services, regardless of their immigration status? |
| CT8 | TB diagnosis | Does national policy include use of rapid diagnostic tests (eg, rapid molecular tests, lateral flow urine lipoarabinomannan assay (LF-LAM)) as the initial diagnostic test for TB in “People Living With HIV/AIDS” (PLHIV)? |
| TP1 | Self-testing | Does national law/policy allow for self-testing? |
| TP2 | Index testing w/ protections | Do national HIV guidelines incorporate index testing/partner notification, while prioritising robust protections for patient confidentiality? |
| TP3 | Compulsory testing | Does national law/policy prohibit compulsory HIV testing? |
| TP4 | Age restrictions on testing and treatment | Can adolescents access HIV testing and treatment without parental consent? |
| TP5 | PrEP | Does national policy make pre-exposure prophylaxis (PrEP) available to eligible populations in accordance with WHO guidelines? |
| TP6 | Harm reduction | Does national/law policy incorporate key harm reduction strategies? |
| TP7 | Comprehensive sexuality education | Does national policy require that comprehensive sexuality education be taught in primary and secondary schools? |
| TP8 | Prisoners prevention | Are both condoms/lubricants and needle/syringe programmes available to prisoners as a matter of policy? |
| S1 | Same-sex criminalisation | Are consensual same-sex sexual acts decriminalised in law? |
| S2 | Sex work criminalisation | Is sex work decriminalised under national law? |
| S3 | Drug use criminalisation | Is personal drug possession/use decriminalised? |
| S4 | HIV exposure criminalisation | Does national law avoid criminalising and prosecuting people for HIV exposure/ transmission? |
| S5 | Non-discrimination protections | Do national/laws policies include protections from discrimination on the basis of sexual orientation, gender identity, and HIV status? |
| S6 | National human rights institutions | Is there an independent national human rights institution to which violations can be reported in compliance with the Paris principles? |
| S7 | Constitutional right to health | Is there an enforceable right to health in the national constitution? |
| S8 | Girls education | Is there a national policy in place to encourage secondary school retention among girls? |
| S9 | Gender-based violence | Does the law explicitly address domestic violence with enforceable penalties? |
| S10 | Civil society | Does national law/policy facilitate open participation by civil society in the AIDS response? |
| HS1 | Task shifting | Does national law/policy allow for nurses or other non-physicians to initiate HIV treatment? |
| HS2 | Health financing | Does national law/policy prioritise sustainable financing for the public health system? |
| HS3 | Universal health coverage (UHC) | Does the national universal health insurance scheme include medications for HIV treatment and PrEP? |
| HS4 | User fees | Are public healthcare services available without user fees at the point of service? |
| HS5 | Access to medicines | Does national law/policy take advantage of ‘TRIPS flexibilities’ for affordable medicines (ie, compulsory licensing/public non-commercial use, parallel import, and Least Developed Country transition provisions)? |
| HS6 | Unique identifiers w/ data protections | Does country have unique identifiers for continuity of care across multiple facilities while protecting patients' privacy? |
| HS7 | Data sharing | Is it country policy to publicly share disaggregated HIV data on a regular basis? |
TB, tuberculosis.
Figure 1HIV policies adopted by country (most recent available data).
Figure 2Average HIV-related policy adoption.
Figure 3South Africa HIV-related policies.
Figure 4Country score card: testing and prevention policies in South Africa.